(-)-ラパマイシン

(-)-ラパマイシン 価格 もっと(24)

メーカー	製品番号	製品説明	CAS番号	包装	価格	更新時間	購入
富士フイルム和光純薬株式会社(wako)	W01LKTR0161	ラパマイシン Rapamycin	53123-88-9	1mg	￥9300	2024-03-01	購入
富士フイルム和光純薬株式会社(wako)	W01LKTR0161	ラパマイシン Rapamycin	53123-88-9	10mg	￥28500	2024-03-01	購入
富士フイルム和光純薬株式会社(wako)	W01LKTR0161	ラパマイシン Rapamycin	53123-88-9	100mg	￥123500	2024-03-01	購入
東京化成工業	R0097	ラパマイシン >98.0%(HPLC) Rapamycin >98.0%(HPLC)	53123-88-9	25mg	￥27800	2024-03-01	購入
Sigma-Aldrich Japan	R0395	ラパマイシン Streptomyces hygroscopicus由来 ≥95% (HPLC), powder Rapamycin from Streptomyces hygroscopicus ≥95% (HPLC), powder	53123-88-9	1mg	￥77200	2024-03-01	購入

(-)-ラパマイシン MSDS

Sirolimus

(-)-ラパマイシン 化学特性,用途語,生産方法

外観

白色〜褐色, 結晶性粉末〜粉末

溶解性

メタノール溶状：試験適合

用途

FK506 の構造類似体であ り、FK506 と同様に FK506 結合タンパク質 （FKBP）と結合しますが、FK506 とは異なり、 カルシニューリンの活性は阻害しません。ラ パマイシンと FKBP の複合体は mTOR に結 合し、mTOR のキナーゼ活性を阻害すること により、IL-2 からのシグナルを阻害します。

用途

移植臓器拒絶の予防のため、リンパ脈管筋腫症の治療のために医学分野で使われている。ヒトにおいて免疫抑制機能を持ち、腎臓移植の拒絶の予防において特に有用である。インターロイキン-2（IL-2）の産生を低下させることによってT細胞およびB細胞の活性化を阻害する。冠動脈ステント（英語版）のコーティング剤としても使われている。

効能

抗悪性腫瘍薬, 免疫抑制薬, mTOR阻害薬

商品名

ラパリムス (ノーベルファーマ); ラパリムス (ノーベルファーマ)

化学的特性

White to Off-White Solid

天然物の起源

Rapamycin was first discovered in 1972 in the soil of Easter Island produced by a bacterium called Streptomyces hygroscopicus. It takes its name from Rapa Nui, the indigenous name for the island. It is known clinically as sirolimus or Rapamune.

使用

Labelled Rapamycin. A triene macrolide antibiotic isolated from Streptomyces hygroscopicus. Name derived from the native word for Easter Island, Rapa?Nui. Used as an immunosuppressant; antirestenotic. This compound contains aproximately 2% d0.;Labeled Sir

適応症

Mechanistic target of rapamycin (mTOR) is a serine/threonine-specific protein kinase in the PI3/PI4-kinase family. mTOR was named after the natural macrolide rapamycin, also known as sirolimus, which was isolated from a soil sample from Easter Island in the 1970s and later evaluated as an immunosuppressive agent. The anticancer activity of rapamycin was discovered in the 1980s, although the mechanismof action and the identification of the rapamycin target, mTOR, were not elucidated until the 1990s. Rapamycin and its macrocyclic analogues, such as temsirolimus (Torisel(R), Wyeth/Pfizer) and everolimus (Afinitor(R), Novartis), are grouped as “rapalogs” that constitute the first-generation mTOR inhibitors.
Rapamycin was approved by the US FDA in 1999 as an immunosuppressive agent to prevent organ rejection in patients receiving kidney transplants. Although a large number of clinical studies have been performed to evaluate the anticancer activities of sirolimus in different types of cancers, such as invasive bladder cancer, breast cancer, and leukemia, most studies show limited efficacy. Outside oncological indications, sirolimus was approved by FDA for the treatment of a rare progressive lung disease lymphangioleiomyomatosis in 2015. Temsirolimus was approved for the treatment of advanced RCC. Everolimus was approved in the EU for the prevention of organ rejection in heart and kidney transplant recipients before FDA approved it in 2009 for the treatment of advanced RCC resistant to sunitinib or sorafenib and for the treatment of advanced or metastatic gastrointestinal and lung tumors in 2016. Additionally, rapamycin and rapalogs are being investigated as antiaging therapeutics or for the treatment of age-related diseases. Studies have revealed that mTOR activity can be retained under hypoxic conditions via mutations in the PI3K pathway, leading to increased translation and hypoxic gene expression and tumor progression.

定義

ChEBI: A macrolide isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.

一般的な説明

Rapamycin is an anti-fungal antibiotic isolated from Streptomyces hygroscopicus. This antibiotic is active against all strains of Candida albicans. It blocks the signal transduction pathways required for the activation of T-helper cells.

生物活性

Antifungal and immunosuppressant. Specific inhibitor of mTOR (mammalian target of Rapamycin). Complexes with FKBP-12 and binds mTOR inhibiting its activity. Inhibits interleukin-2-induced phosphorylation and activation of p70 S6 kinase.

(-)-ラパマイシン 上流と下流の製品情報

原材料

準備製品

(-)-ラパマイシン 生産企業

名前	電話番号	電子メール	国籍	製品カタログ	優位度
Shanghai Minbiotech Co., Ltd.	+8617315815539	sales@minbiotech.com	CHINA	129	58
Hangzhou Benoy Chemical Co., Ltd	+8617342059697	sales@benoychem.com	China	315	58
Hebei Lingding Biotechnology Co., Ltd.	+86-18031140164 +86-19933155420	erin@hbldbiotech.com	China	878	58
Seasons Biotechnology Co., Ltd.	+86-0576-89232655 +86-13566878689	info@seasonsbio.com	China	46	58
Guangzhou Tengyue Chemical Co., Ltd.	+86-86-18148706580 +8618826483838	evan@tyvovo.com	China	152	58
BOC Sciences	+16314854226	inquiry@bocsci.com	United States	19743	58
Hebei Mojin Biotechnology Co., Ltd	+8613288715578	sales@hbmojin.com	China	12457	58
Henan Tengmao Chemical Technology Co. LTD	+8615238638457	salesvip2@hntmhg.com	China	415	58
Hangzhou ICH Biofarm Co., Ltd	+undefined8613073685410	sales@ichemie.com	China	985	58
Shaanxi Haibo Biotechnology Co., Ltd	+undefined18602966907	qinhe02@xaltbio.com	China	1000	58

53123-88-9((-)-ラパマイシン)キーワード:

---

• 53123-88-9
• AY 22989
• 23,27-EPOXY-3H-PYRIDO(2,1-C)(1,4)OXAAZACYCLOHENTRIACONTINE
• NSC-226080
• RAPAMYCIN
• RAPAMYCIN, STREPTOMYCES HYGROSCOPICUS
• RPM
• antibioticay22989
• (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
• RAPAMYCIN FROM STREPTOMYCESHYGROSCOPICUS RESEARCH GRADE
• (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-Methoxycyclohexyl]propan-2-yl]-19,30-diMethoxy-15,17,21,23,29,35-hexaMethyl-11,36-dioxa-4-azatricyclo[30.3.1.0^{4,9}]hexatriaconta-16,24,26,28-te
• (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-Methoxycyclohexyl]-1-Methylethyl]-10,21-diMethoxy-6,8,12,14,20,26-hexaMethy
• RapaMycin RapaMuneTM
• RapaMycin-d3 (SiroliMus-d3)
• SiroliMus, AY 22989, SIIA 9268A
• RapaMicin(siroliMus )
• AY 22989，NSC-2260804
• Sirolimus Rapamicin(sirolimus )
• Rapamycin Sirolimus 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
• Rapamycin 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
• rapamycinfromstreptomyces*hygroscopicus
• sila9268a
• WYETH RAPAMYCIN, 40MG
• RAPAMYCIN 40MG
• WYETH RAPAMYCIN, 10MG
• WYETH RAPAMYCIN, 1GM
• RAPAMYCIN 10MG
• RAPAMYCIN 1GM
• RAPAMYCIN, STANDARD WITH MS, NMR RESULT
• RAPAMYCIN , 99+%
• Sirolimus, RAPA, RPM,
• シロリムス
• ラパマイシン
• (-)-ラパマイシン
• 抗生物質AY-22989
• EZSOLUTION™ RAPAMYCIN
• ラパマイシン(異性体混合物)
• シロリムス 溶液
• ラパマイシン STREPTOMYCES HYGROSCOPICUS由来
• ラパマイシン（異性体混合物）【シロリムス】
• EZSolution™ ラパマイシン
• シロリムス (JAN)
• (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-ジヒドロキシ-12-[(2R)-1-[(1S,3R,4R)-4-ヒドロキシ-3-メトキシシクロヘキシル]プロパン-2-イル]-19,30-ジメトキシ-15,17,21,23,29,35-ヘキサメチル-11,36-ジオキサ-4-アザトリシクロ[30.3.1.04,9]ヘキサトリアコンタ-16,24,26,28-テトラエン-2,3,10,14,20-ペンタオン
• (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-ヘキサデカヒドロ-9,27-ジヒドロキシ-3-[(1R)-2-[(1S,3R,4R)-4-ヒドロキシ-3-メトキシシクロヘキシル]-1-メチルエチル]-10,21-ジメトキシ-6,8,12,14,20,26-ヘキサメチル-23,27-エポキシ-3H-ピリド[2,1-c][1,4]オキサアザシクロヘントリアコンチン-1,5,11,28,29(4H,6H,31H)-ペンタオン
• ラパリムス
• マクロライド系抗生物質
• 免疫抑制薬